Potential use of Magnolia officinalis bark polyphenols in the treatment of cannabis dependence

• Published in: Medical hypotheses Vol. 83; no. 6; pp. 673 - 676
• Main Authors: Coppola, Maurizio, Mondola, Raffaella
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 01-12-2014
• Subjects: Animals; Biphenyl Compounds - therapeutic use; Cannabis; Humans; Inflammation; Internal Medicine; Lignans - therapeutic use; Magnolia - chemistry; Marijuana Abuse - drug therapy; Plant Bark - chemistry; Plant Extracts - therapeutic use; Polyphenols - chemistry; Rats; Receptor, Cannabinoid, CB1 - metabolism; Receptor, Cannabinoid, CB2 - metabolism; Receptors, G-Protein-Coupled - metabolism
• ISSN: 0306-9877; 1532-2777
• DOI: 10.1016/j.mehy.2014.09.015

Abstract In recent years, epidemiological data confirm that cannabis-related emergencies, cannabis-use disorders and dependence are significantly increased. Cannabis is generally considered a little dangerous substances of abuse, however, chronic consumption has been associated to the development of mental disorders, cognitive deficits, chronic bronchitis, emphysema, increased risk of myocardial infarction in the hour after use, increased mortality after myocardial infarction, liver inflammation and steatosis in patients affected by hepatitis C. In this article we described the pharmacological characteristics of Magnolia officinalis bark active principles suggesting a potential application in the treatment of both cannabis dependence and cannabis-related disorders.